Market research
17DN.F Arcadia Biosciences, Inc
F EUR Consumer Defensive
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 152K
- P/E ratio
- Not available
- Analyst target
- 6.23
- Dividend yield
- 0.0%
- Beta
- 0.15
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- ISIN
- Not available
- Market cap
- 152K
- P/E ratio
- Not available
- Analyst target
- 6.23
- Dividend yield
- 0.0%
- Beta
- 0.15
About
About Arcadia Biosciences, Inc
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care. The company was incorporated in 2002 and is headquartered in Davis, California.
Research context
Arcadia Biosciences, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 17DN.F discussion.
5 years, 6 months ago
Arcadia Biosciences, Inc is currently in a long term downtrend where the price is trading 10.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Basic Materials sector with a price to sales ratio of 3.2.
Arcadia Biosciences, Inc's total revenue rose by 1613.9% to $7M since the same quarter in the previous year.
Its net income has increased by 242.5% to $9M since the same quarter in the previous year.
Finally, its free cash flow fell by 25.6% to $-7M since the same quarter in the previous year.
Based on the above factors, Arcadia Biosciences, Inc gets an overall score of 3/5.